Search Results 771-780 of 17475 for Strabismus

  1. Mayo Clinic

    ... . IMG-20358161. Home; DirectAnteriorHip_Fig2_Sm. 3X your impact! Give Now! Your gift can go 3X as far to shape the future of cancer care.

  2. A Phase 2/3 Study To Investigate The Safety And Efficacy Of Brepocitinib In Adults With Lichen Planopilaris (ALPINE) - Mayo Clinic

    The purpose of this study is to determine the safety and efficacy of brepocitinib (a tyrosine kinase [TYK]2/Janus kinase [JAK]1 inhibitor) in adult participants ...

  3. Stroke - Doctors and departments - Mayo Clinic

    Promptly spotting stroke symptoms leads to faster treatment and less damage to the brain.

  4. Obstructive sleep apnea - Doctors and departments - Mayo Clinic

    Mayo Clinic experts trained in sleep medicine study new diagnosis and treatment options for obstructive sleep apnea, sleep-disordered breathing and other sleep ...

  5. Dysphagia - Doctors and departments - Mayo Clinic

    Having trouble swallowing? Learn more about what causes this common issue, along with therapies for treating the condition.

  6. Mayo Clinic

    Fuel groundbreaking medical research! ... Your donation powers the future of medicine and helps save lives. Give Today.

  7. (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive - Mayo Clinic

    (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive. Print ...

  8. Neurology - Clinical trials

    The purpose of this study is to develop prognostic and diagnostic blood tests for symptomatic brain hemorrhage in patients diagnosed with cavernous angiomas ...

  9. News - Sanjeet S. Grewal, M.D. - Mayo Clinic

    Fuel groundbreaking medical research! ... Your donation powers the future of medicine and helps save lives. Give Today.

  10. A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors - Mayo Clinic

    The atezolizumab plus obinutuzumab) (Arm E) will enroll participants with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).